NDT Advance Access originally published online on October 2, 2006
Nephrology Dialysis Transplantation 2007 22(1):293; doi:10.1093/ndt/gfl500
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism
Email: astkar@med.auth.gr
| The first 10% of the full text of this article appears below. |
Sir,
Eplerenone is the second oral aldosterone antagonist available for the treatment of essential hypertension and congestive heart failure. Spironolactone, the first aldosterone antagonist, although effective for the above conditions, has progestational and antiandrogenic adverse effects due to its non-specific binding to various steroid receptors.
We report the case of a 54-year-old Caucasian man, who was admitted to
Second Propedeutic Department of Internal Medicine
Medical School
Aristotle University of Thessaloniki
Hippokration Hospital
Thessaloniki
Greece
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Karagiannis, K. Tziomalos, A. I Kakafika, V. G Athyros, F. Harsoulis, and D. P Mikhailidis Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas Endocr. Relat. Cancer, September 1, 2008; 15(3): 693 - 700. [Abstract] [Full Text] [PDF] |
||||
